Dourado, MR, Machado, RA, Paranaíba, LMR, et al. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas. Oral Dis. 2021; 00: 1– 9. https://doi.org/10.1111/odi.13809
Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas
|Author:||Dourado, Mauricio Rocha1; Machado, Renato Assis1,2; Ribeiro Paranaíba3, Lívia Máris3;|
1Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil
2Hospital for Rehabilitation of Craniofacial Anomalies, University of São Paulo (HRAC/USP), Bauru, Brazil
3Department of Pathology and Parasitology, Institute of Biomedical Sciences, Federal University of Alfenas, Alfenas, Brazil
4Department of Oral Pathology and Diagnosis, Faculty of Dentistry, Universidad de Valparaíso, Valparaíso, Chile
5Lady Davis Institute for Medical Research, Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada
6Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, QC, Canada
7Department of Oral Pathology and Oral Medicine, Dental School, Western Paraná State University, Cascavel, Brazil
8Cancer and Translational Medicine Research Unit, Faculty of Medicine and Medical Research Centre Oulu, Oulu University Hospital, University of Oulu, Oulu, Finland
9Department of Pathology, Institute of Oral and Maxillofacial Disease, Helsinki University Hospital, University of Helsinki and HUSLAB, Helsinki, Finland
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2021062840256
John Wiley & Sons,
|Publish Date:|| 2022-02-22
Background: Trophoblast cell surface antigen 2 (TROP2) has unclear clinical role in oral squamous cell carcinomas (OSCC). Here, we investigated the association of TROP2 immunoexpression with clinicopathological parameters and survival of OSCC patients.
Subjects and Methods: Cancer-specific survival (CSS) and disease-free survival (DFS) were assessed in a cohort composed of 266 OSCC. An independent cohort with 88 OSCC samples matched with the normal oral tissue, as well as 17 metastatic lymph nodes, was used for validation.
Results: Multivariate analysis showed TROP2 as an independent marker of favorable prognosis for both CSS (HR: 0.60, 95% CI: 0.40–0.90, p = .01) and DFS (HR: 0.57, 95% CI: 0.36–0.89, p = .01). Furthermore, TROP2 protein expression was significantly higher in morphologically normal tissues compared to primary tumors (p < .0001) and lymph node metastases (p = .001), and it was significantly associated with CSS (HR: 0.26, 95% CI: 0.09–0.74, p = .008) in the validation cohort. A pooled mRNA analysis performed on the Oncomine™ database confirmed the underexpression in OSCC compared with normal tissues (p = .014).
Conclusions: In summary, our results point to a favorable prognostic significance of TROP2 overexpression in a large cohort of oral cancer patients, suggesting it as an attractive clinical marker.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP. Grant Numbers: 2018/16077-6, 2017/26764-8; Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq. Grant Number: 303589/2019-1; Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG. Grant Number: APQ 00205.16.
The data that support the findings of this study are available from the corresponding author upon reasonable request.
© 2021 Wiley Periodicals LLC. This is the peer reviewed version of the following article: Dourado, MR, Machado, RA, Paranaíba, LMR, et al. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas. Oral Dis. 2021; 00: 1– 9, which has been published in final form at https://doi.org/10.1111/odi.13809. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.